Sangamo Therapeutics, Inc.

OTC: SGMOQ · Healthcare · Biotechnology

PublicHQ Richmond, CA · Contra CostaReports USD

#1 of 1,418 Healthcare companies by revenue

EA Score

——

FH —DQ —GM —SS 71

v0.1 · 5/100 weight · pillars only

↑ listing tenure, workforce scale · ↓ market scale, workforce scale

Methodology →

Revenue TTM

—

Rev growth YoY (TTM)

needs 8 qtrs

Net income (FY)

—

Employees

142

as of 2026-09-02

Market cap

$66.3M

as of 2026-09-02

Financials — latest annual

SEC EDGAR · USD-normalized

ConceptUSDNativeFY

No filed financials — private or non-XBRL filer.

Revenue by segment

No segmentation disclosed for this filer. n/a

The read

What is Sangamo Therapeutics, Inc.’s financial profile?

Sangamo Therapeutics, Inc. has no structured financials on file — private or non-XBRL filer.

Peers · Healthcare

Acrivon Therapeutics, Inc. Common Stock——Cingulate Inc.——BioStem Technologies, Inc.——Boundless Bio, Inc.——NDT Pharmaceuticals Inc.——MiNK Therapeutics, Inc.——

Neighbors

Contra Costa →

The Cooper Companies, Inc.$4.1B86A Bio-Rad Laboratories, Inc.$2.6B84B+Mechanics Bank$49.7M46D Central Garden & Pet Company$3.1B70B Five9, Inc.$1.1B73B PHI Group, Inc.$674.4M——

Key facts

CEOAlexander D. Macrae

SectorHealthcare

IndustryBiotechnology

HeadquartersRichmond, CA

ExchangeOTC: SGMOQ

Employees142

IPO date2000-04-06

Latest filings

No filings loaded — no CIK (non-SEC filer).

Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.